Retention and Other Efficacy Outcomes With Long-Acting Injectable Buprenorphine (Buvidal ® ) in France: A National Retrospective Cross-Sectional Study (OPALE 2)
Abstract
Background: Opioid agonist treatment (OAT) is the mainstay for opioid use disorder (OUD). Long-acting injectable buprenorphine may address limitations of daily medications by reducing treatment burden and improving engagement. This study assessed retention and patient-reported outcomes with Buvidal ® in France. Methods: This multicenter, observational, retrospective study analyzed medical records of adults diagnosed with OUD who received ≥1 Buvidal ® injection between July 2021 and August 2023. The primary endpoint was retention at 6 months. Key secondary endpoints included changes in opioid consumption, perceived improvement in OUD using the Patient Global Impression of Change (PGIC) scale, distancing from OUD, reduction in craving, and satisfaction with Buvidal ® treatment. Results: Among 101 participants (mean age 43.9 years; 72.3% male; 98.0% switched to Buvidal ® from previous OAT), 74 (73.3%) were retained on Buvidal ® at 6 months. Of those using non-prescribed or misused opioids at baseline, decreased consumption of non-prescribed or misused opioids during treatment with Buvidal ® was reported by 80.0% (16/20) of retained participants and 66.7% (8/12) of non-retained participants. A significantly higher proportion of retained than non-retained participants reported improvement in OUD on PGIC (85.1% [63/74] vs 40.7% [11/27]; P < .001), increased distancing from OUD (90.5% [67/74] vs 70.4% [19/27]; P = .02), and reduced craving (91.9% [68/74] vs 66.7% [18/27]; P < .001). Satisfaction with Buvidal ® was high overall (89.1% [90/101]), with 98.6% (73/74) of retained participants satisfied compared with 63.0% (17/27) of non-retained participants ( P < .001). Among retained participants, 91.9% (68/74) expressed willingness to continue Buvidal ® treatment beyond 6 months. Conclusions: Nearly three-quarters of participants initiating Buvidal ® were retained in treatment at 6 months. Patient-reported outcomes indicated high satisfaction, perceived improvement in OUD, and reductions in opioid consumption and craving, even among individuals largely stabilized on OAT at baseline. These findings suggest that Buvidal ® may support sustained engagement and meaningful improvements in patient experience under real-world conditions.
Related
- Perceptions of psychiatrists toward long-acting injectable antipsychotics: A cross-sectional survey from Fujian, China
- Comparison of Five Benzodiazepine-Receptor Agonists on Buprenorphine-Induced μ-Opioid Receptor Regulation
- Efficacy analysis of the Turnbull–Cutait procedure in refractory perianal Crohn’s disease: a two-centre retrospective study
- Evaluating the efficacy of a novel endometrial receptivity test in improving pregnancy outcomes for Chinese in vitro fertilization patients: a single-center retrospective study
- Efficacy evaluation of the cervical posterior “keyhole technique” in the treatment of cervical radiculopathy: A retrospective case series
BibTeX
@article{deschenau2026retention,
title = {{Retention and Other Efficacy Outcomes With Long-Acting Injectable Buprenorphine (Buvidal ® ) in France: A National Retrospective Cross-Sectional Study (OPALE 2)}},
author = {Alice Deschenau and Pascal Melin and Julien Azuar and Benjamin Touchon and Isabelle Vinel-Jacquet and Benoit Trojak and Lisa Blecha and Julien Cabé and Margaux Kosim and Geoffroy Dupeyron and Jean-Pierre Daulouède and Georges Brousse and Mathieu Chappuy and Benjamin Rolland},
journal = {Substance Use \& Addiction Journal},
year = {2026},
month = may,
doi = {10.1177/29767342261433342},
url = {https://hal.science/hal-05804420v1},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Retention and Other Efficacy Outcomes With Long-Acting Injectable Buprenorphine (Buvidal ® ) in France: A National Retrospective Cross-Sectional Study (OPALE 2)
AU - Alice Deschenau
AU - Pascal Melin
AU - Julien Azuar
AU - Benjamin Touchon
AU - Isabelle Vinel-Jacquet
AU - Benoit Trojak
AU - Lisa Blecha
AU - Julien Cabé
AU - Margaux Kosim
AU - Geoffroy Dupeyron
AU - Jean-Pierre Daulouède
AU - Georges Brousse
AU - Mathieu Chappuy
AU - Benjamin Rolland
PY - 2026
DA - 2026/05/14
JO - Substance Use & Addiction Journal
DO - 10.1177/29767342261433342
UR - https://hal.science/hal-05804420v1
AB - Background: Opioid agonist treatment (OAT) is the mainstay for opioid use disorder (OUD). Long-acting injectable buprenorphine may address limitations of daily medications by reducing treatment burden and improving engagement. This study assessed retention and patient-reported outcomes with Buvidal ® in France. Methods: This multicenter, observational, retrospective study analyzed medical records of adults diagnosed with OUD who received ≥1 Buvidal ® injection between July 2021 and August 2023. The primary endpoint was retention at 6 months. Key secondary endpoints included changes in opioid consumption, perceived improvement in OUD using the Patient Global Impression of Change (PGIC) scale, distancing from OUD, reduction in craving, and satisfaction with Buvidal ® treatment. Results: Among 101 participants (mean age 43.9 years; 72.3% male; 98.0% switched to Buvidal ® from previous OAT), 74 (73.3%) were retained on Buvidal ® at 6 months. Of those using non-prescribed or misused opioids at baseline, decreased consumption of non-prescribed or misused opioids during treatment with Buvidal ® was reported by 80.0% (16/20) of retained participants and 66.7% (8/12) of non-retained participants. A significantly higher proportion of retained than non-retained participants reported improvement in OUD on PGIC (85.1% [63/74] vs 40.7% [11/27]; P < .001), increased distancing from OUD (90.5% [67/74] vs 70.4% [19/27]; P = .02), and reduced craving (91.9% [68/74] vs 66.7% [18/27]; P < .001). Satisfaction with Buvidal ® was high overall (89.1% [90/101]), with 98.6% (73/74) of retained participants satisfied compared with 63.0% (17/27) of non-retained participants ( P < .001). Among retained participants, 91.9% (68/74) expressed willingness to continue Buvidal ® treatment beyond 6 months. Conclusions: Nearly three-quarters of participants initiating Buvidal ® were retained in treatment at 6 months. Patient-reported outcomes indicated high satisfaction, perceived improvement in OUD, and reductions in opioid consumption and craving, even among individuals largely stabilized on OAT at baseline. These findings suggest that Buvidal ® may support sustained engagement and meaningful improvements in patient experience under real-world conditions.
SN - 2976-7342
SN - 2976-7350
ER -